Kathy O'Briant

10.2k total citations · 1 hit paper
39 papers, 8.3k citations indexed

About

Kathy O'Briant is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Kathy O'Briant has authored 39 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 14 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Kathy O'Briant's work include Monoclonal and Polyclonal Antibodies Research (9 papers), Toxin Mechanisms and Immunotoxins (8 papers) and Ovarian cancer diagnosis and treatment (7 papers). Kathy O'Briant is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), Toxin Mechanisms and Immunotoxins (8 papers) and Ovarian cancer diagnosis and treatment (7 papers). Kathy O'Briant collaborates with scholars based in United States, South Africa and United Kingdom. Kathy O'Briant's co-authors include Charles W. Drescher, Nicole Urban, Muneesh Tewari, Beatrice S. Knudsen, Rachael K. Parkin, Brian R. Fritz, Patrick S. Mitchell, Stacia K. Wyman, Evan M. Kroh and Robert Gentleman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

Kathy O'Briant

39 papers receiving 8.2k citations

Hit Papers

Circulating microRNAs as stable blood-based markers for c... 2008 2026 2014 2020 2008 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Circulating microRNAs as stable blood-based markers for cancer detection
    2008 6.5k citations Patrick S. Mitchell, Rachael K. Parkin et al. Proceedings of the National Academy of Sciences profile →

Peers

Kathy O'Briant
Era L. Pogosova‐Agadjanyan United States
Derek L. Stirewalt United States
Daniel Martin United States
Evan M. Kroh United States
Fabio Petrocca United States
Rachael K. Parkin United States
Giulia Taraboletti Italy
Rajesha Rupaimoole United States
Brian R. Fritz United States
Heidi Schwarzenbach Germany
Era L. Pogosova‐Agadjanyan United States
Kathy O'Briant
Citations per year, relative to Kathy O'Briant Kathy O'Briant (= 1×) peers Era L. Pogosova‐Agadjanyan

Countries citing papers authored by Kathy O'Briant

Since Specialization
Citations

This map shows the geographic impact of Kathy O'Briant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathy O'Briant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathy O'Briant more than expected).

Fields of papers citing papers by Kathy O'Briant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathy O'Briant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathy O'Briant. The network helps show where Kathy O'Briant may publish in the future.

Co-authorship network of co-authors of Kathy O'Briant

This figure shows the co-authorship network connecting the top 25 collaborators of Kathy O'Briant. A scholar is included among the top collaborators of Kathy O'Briant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathy O'Briant. Kathy O'Briant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Knouf, Emily C., Kavita S. Garg, Jason D. Arroyo, et al.. (2011). An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Research. 40(2). 499–510. 58 indexed citations
2.
Urban, Nicole, Jason D. Thorpe, Lindsay Bergan, et al.. (2011). Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer. JNCI Journal of the National Cancer Institute. 103(21). 1630–1634. 40 indexed citations
3.
Amon, Lynn M., Wendy Law, Matthew Fitzgibbon, et al.. (2010). Integrative Proteomic Analysis of Serum and Peritoneal Fluids Helps Identify Proteins that Are Up-Regulated in Serum of Women with Ovarian Cancer. PLoS ONE. 5(6). e11137–e11137. 30 indexed citations
4.
Wyman, Stacia K., Rachael K. Parkin, Patrick S. Mitchell, et al.. (2009). Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA Libraries. PLoS ONE. 4(4). e5311–e5311. 193 indexed citations
5.
Anderson, Garnet L., Martin McIntosh, LieLing Wu, et al.. (2009). Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study. JNCI Journal of the National Cancer Institute. 102(1). 26–38. 153 indexed citations
6.
Bendoraite, Ausra, Emily C. Knouf, Kavita S. Garg, et al.. (2009). Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transition. Gynecologic Oncology. 116(1). 117–125. 168 indexed citations
7.
Mitchell, Patrick S., Rachael K. Parkin, Evan M. Kroh, et al.. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences. 105(30). 10513–10518. 6512 indexed citations breakdown →
8.
Faça, Vítor M., Aviva P. Ventura, Sharon J. Pitteri, et al.. (2008). Proteomic Analysis of Ovarian Cancer Cells Reveals Dynamic Processes of Protein Secretion and Shedding of Extra-Cellular Domains. PLoS ONE. 3(6). e2425–e2425. 105 indexed citations
9.
Stone, Brad, Michèl Schummer, Pamela J. Paley, et al.. (2003). Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. International Journal of Cancer. 104(1). 73–84. 64 indexed citations
10.
Bennett, Craig L., Mary E. Brunkow, Fred Ramsdell, et al.. (2001). A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA→AAUGAA) leads to the IPEX syndrome. Immunogenetics. 53(6). 435–439. 190 indexed citations
11.
Xu, Fengfeng, Steven A. Leadon, Yinhua Yu, et al.. (2000). Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.. PubMed. 6(8). 3334–41. 11 indexed citations
12.
Kim, Young Chul, Youjia Cao, Diana M. Pitterle, Kathy O'Briant, & Gerold Bepler. (2000). SSA/RO52gene and expressed sequence tags in an 85 kb region of chromosome segment 11p15.5. International Journal of Cancer. 87(1). 61–67. 2 indexed citations
13.
Dean, Gillian S., Lajos Pusztai, Fengfeng Xu, et al.. (1998). Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.. PubMed. 4(10). 2545–50. 24 indexed citations
14.
Xu, Fengfeng, C. Boyer, Kathy O'Briant, et al.. (1997). Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.. PubMed. 3(9). 1629–34. 61 indexed citations
15.
O'Briant, Kathy & Gerold Bepler. (1997). Delineation of the centromeric and telomeric chromosome segment 11p15.5 lung cancer suppressor regions LOH11A and LOH11B. Genes Chromosomes and Cancer. 18(2). 111–114. 28 indexed citations
16.
Woolas, Robert, Mark R. Conaway, Fengji Xu, et al.. (1995). Combinations of Multiple Serum Markers Are Superior to Individual Assays for Discriminating Malignant from Benign Pelvic Masses. Gynecologic Oncology. 59(1). 111–116. 90 indexed citations
17.
O'Briant, Kathy, et al.. (1993). Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.. Journal of Clinical Investigation. 92(5). 2440–2447. 16 indexed citations
18.
Crews, Jennie R., Lisa A. Maier, Yu Yin, et al.. (1992). A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast‐cancer cell lines. International Journal of Cancer. 51(5). 772–779. 14 indexed citations
19.
O'Briant, Kathy, Verda J. Hunter, L. Daly, et al.. (1992). Ha-ras polymorphisms in epithelial ovarian cancer. Gynecologic Oncology. 45(3). 299–302. 4 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Era L. Pogosova‐Agadjanyan Breakdown of academic impact, for papers by Derek L. Stirewalt Breakdown of academic impact, for papers by Daniel Martin Breakdown of academic impact, for papers by Evan M. Kroh Breakdown of academic impact, for papers by Fabio Petrocca Breakdown of academic impact, for papers by Rachael K. Parkin Breakdown of academic impact, for papers by Giulia Taraboletti Breakdown of academic impact, for papers by Rajesha Rupaimoole Breakdown of academic impact, for papers by Brian R. Fritz Breakdown of academic impact, for papers by Heidi Schwarzenbach
Rankless by CCL
2026